Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quadrivalent influenza split vaccine (Anhui Zhifei Longkema)
- Development stage
- Unknown
- Lead developer
- Anhui Zhifei Longcom Biopharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The quadrivalent influenza split vaccine developed by Anhui Zhifei Longkema Biopharmaceutical is an inactivated split virion vaccine designed for the prevention of seasonal influenza. It contains antigens from four influenza virus strains: two A subtypes (H1N1 and H3N2) and two B lineages (Victoria and Yamagata). By presenting antigenic epitopes from these split virus particles, the vaccine stimulates the immune system to produce hemagglutination inhibition (HI) antibodies, providing broader protection than trivalent vaccines. It was approved in China in March 2025 and has been evaluated in clinical trials for safety and immunogenicity in populations including children aged 6-35 months.
- Other names
- 四价流感病毒裂解疫苗Quadrivalent Influenza Split Vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Quadrivalent influenza split vaccine (Anhui Zhifei Longkema).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quadrivalent influenza split vaccine (Anhui Zhifei Longkema).